Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((reverse stock split 1:10))

Author: Benzinga Newsdesk | July 18, 2024 05:12pm
Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy, adjusts target to $40 from $4 ((reverse stock split 1:10)).

Posted In: ADVM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist